Bringing the Oncology Community Together

Dr. Yarnold on Hypofractionation in the START Trials

John Yarnold, MBBS
Published Online: Friday, December 7, 2012
John Yarnold, MBBS, professor of clinical oncology at The Institute of Cancer Research in London and honorary consultant at The Royal Marsden NHS Foundation Trust, discusses results from the START A and B trials that examined hypofractionated radioatherapy for women with early breast cancer.

The START trials enrolled a total of 4451 women with completely excised invasive breast cancer. In START A, approximately 2236 patients received either 50 Gy in 25 fractions for five weeks compared to 41.6 Gy or 39 Gy in 13 fractions for five weeks. In the START B trial, 2215 patients were randomized to receive either 50 Gy in 25 fractions for five weeks or 40 Gy in 15 fractions for 3 weeks.

In the START B trial, administering 40 Gy over 3 weeks produced fewer adverse events and was noninferior at tumor control compared to 50 Gy for 5 weeks.

Yarnold notes that 40 Gy for 3 weeks in 15 fractions has been the current standard treatment option in the United Kingdom, since 2009. This approach has proven to be approximately 20% less harmful to patients while producing similar tumor control to 50 Gy for 5 weeks, which is the standard in the United States.

<<< View coverage from the 2012 SABCS

Related Articles
Role of Radiation Therapy in Hodgkin Lymphoma
Panelists discuss the evolving role of radiation therapy in Hodgkin lymphoma and whether new approaches lessen the long-term toxicity traditionally associated with this treatment modality.
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Experts Support Broader Pertuzumab Use in HER2-Positive Breast Cancer
The recent approval of pertuzumab as part of a combination neoadjuvant treatment for patients with early-stage breast cancer has paved the way for wider use of the regimen in preoperative settings.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.